1![Attachment 1 Evaluation Test Name number as assigned during the Attachment 1 Evaluation Test Name number as assigned during the](https://www.pdfsearch.io/img/16a19542537c5d61848613049095eeaf.jpg) | Add to Reading ListSource URL: www.engage.england.nhs.ukLanguage: English - Date: 2015-03-24 06:50:34
|
---|
2![A
Phase
III
Multicenter
Study
of
SBC-‐102
(sebelipase
alfa)
in
patients
with
Lysosomal
Acid
Lipase
(LAL)
Deficiency.
Lysosomal
Acid A
Phase
III
Multicenter
Study
of
SBC-‐102
(sebelipase
alfa)
in
patients
with
Lysosomal
Acid
Lipase
(LAL)
Deficiency.
Lysosomal
Acid](https://www.pdfsearch.io/img/be434437d6d1e9e17c13a467bd0f2f20.jpg) | Add to Reading ListSource URL: www.raredisorders.caLanguage: English - Date: 2013-04-09 16:16:18
|
---|
3![SYNAGEVA BIOPHARMA™ HIGHLIGHTS DATA AT THE INTERNATIONAL CONGRESS OF INBORN ERRORS OF METABOLISM LEXINGTON, Mass., September 4, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company dev SYNAGEVA BIOPHARMA™ HIGHLIGHTS DATA AT THE INTERNATIONAL CONGRESS OF INBORN ERRORS OF METABOLISM LEXINGTON, Mass., September 4, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company dev](https://www.pdfsearch.io/img/652557ca31a04045ea72263a7bd6d689.jpg) | Add to Reading ListSource URL: www.synageva.comLanguage: English - Date: 2013-09-04 07:10:51
|
---|
4![SYNAGEVA BIOPHARMA™ REPORTS 2013 FULL YEAR FINANCIAL RESULTS LEXINGTON, Mass., March 3, [removed]Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for SYNAGEVA BIOPHARMA™ REPORTS 2013 FULL YEAR FINANCIAL RESULTS LEXINGTON, Mass., March 3, [removed]Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for](https://www.pdfsearch.io/img/48377d9ebd9bea6e3a29b8ade4327978.jpg) | Add to Reading ListSource URL: www.synageva.comLanguage: English - Date: 2014-03-03 16:19:48
|
---|
5![SYNAGEVA BIOPHARMA™ ANNOUNCES PRESENTATIONS AND A SATELLITE SYMPOSIUM AT THE NATIONAL LIPID ASSOCIATION MEETING LEXINGTON, Mass., May 31, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical c SYNAGEVA BIOPHARMA™ ANNOUNCES PRESENTATIONS AND A SATELLITE SYMPOSIUM AT THE NATIONAL LIPID ASSOCIATION MEETING LEXINGTON, Mass., May 31, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical c](https://www.pdfsearch.io/img/fc181ff262c4ff42399139e800daab1f.jpg) | Add to Reading ListSource URL: www.synageva.comLanguage: English - Date: 2013-05-31 11:41:10
|
---|
6![LATE ONSET LAL DEFICIENCY (CESD) LITERATURE REVIEW PUBLISHED IN THE JOURNAL OF HEPATOLOGY LEXINGTON, Mass., March 26, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a clinical stage biopharmaceutical company LATE ONSET LAL DEFICIENCY (CESD) LITERATURE REVIEW PUBLISHED IN THE JOURNAL OF HEPATOLOGY LEXINGTON, Mass., March 26, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a clinical stage biopharmaceutical company](https://www.pdfsearch.io/img/4e9ffc24ce45b7f0188141cb9e3ec1e0.jpg) | Add to Reading ListSource URL: www.synageva.comLanguage: English - Date: 2013-03-26 07:29:22
|
---|
7![SYNAGEVA BIOPHARMA™ HIGHLIGHTS SEBELIPASE ALFA AND LAL DEFICIENCY DATA AT THE LYSOSOMAL DISEASE NETWORK (LDN) WORLD SYMPOSIUM™ LEXINGTON, Mass., February 13, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), SYNAGEVA BIOPHARMA™ HIGHLIGHTS SEBELIPASE ALFA AND LAL DEFICIENCY DATA AT THE LYSOSOMAL DISEASE NETWORK (LDN) WORLD SYMPOSIUM™ LEXINGTON, Mass., February 13, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA),](https://www.pdfsearch.io/img/ac7412d61f7f5eac4337badf18af2161.jpg) | Add to Reading ListSource URL: www.synageva.comLanguage: English - Date: 2014-02-13 14:27:52
|
---|
8![SYNAGEVA BIOPHARMA™ REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS LEXINGTON, Mass., July 30, [removed]Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products SYNAGEVA BIOPHARMA™ REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS LEXINGTON, Mass., July 30, [removed]Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products](https://www.pdfsearch.io/img/d698e0c72d74913d3ae56ccdcbcae110.jpg) | Add to Reading ListSource URL: www.synageva.comLanguage: English - Date: 2014-08-04 12:07:09
|
---|
9![SYNAGEVA BIOPHARMA™ ISSUED U.S. PATENT FOR TREATMENT OF LAL DEFICIENCY LEXINGTON, Mass., March 4, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products SYNAGEVA BIOPHARMA™ ISSUED U.S. PATENT FOR TREATMENT OF LAL DEFICIENCY LEXINGTON, Mass., March 4, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products](https://www.pdfsearch.io/img/2a29c114b53069b8297d3ea25c7dc7fa.jpg) | Add to Reading ListSource URL: www.synageva.comLanguage: English - Date: 2014-03-04 08:05:19
|
---|
10![SYNAGEVA BIOPHARMA™ REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF SEBELIPASE ALFA IN CHILDREN AND ADULTS WITH LAL DEFICIENCY Phase 3 Study Meets Primary Endpoint and Six Secondary Endpoints Across Multiple Di SYNAGEVA BIOPHARMA™ REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF SEBELIPASE ALFA IN CHILDREN AND ADULTS WITH LAL DEFICIENCY Phase 3 Study Meets Primary Endpoint and Six Secondary Endpoints Across Multiple Di](https://www.pdfsearch.io/img/b52e7c5e5494f1b42754c65dc1206914.jpg) | Add to Reading ListSource URL: www.synageva.comLanguage: English - Date: 2014-10-09 07:26:12
|
---|